Molecular Partners Reports H1 2024 Corporate Highlights and Financials

First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025

Strategic collaboration agreement signed with Orano Med to co-develop ²¹²Pb-based RDT candidates for multiple oncology targets, including MP0712